68Ga-PSMA-11 PET/CT versus 68Ga-PSMA-11 PET/MRI for the detection of biochemically recurrent prostate cancer: a systematic review and meta-analysis
R Huang, Y Li, H Wu, B Liu, X Zhang, Z Zhang - Frontiers in Oncology, 2023 - frontiersin.org
Purpose Our aim was to conduct a meta-analysis and systematic review in order to compare
the diagnostic efficacy of 68Ga-PSMA-11 PET/CT and 68Ga-PSMA-11 PET/MRI in patients …
the diagnostic efficacy of 68Ga-PSMA-11 PET/CT and 68Ga-PSMA-11 PET/MRI in patients …
Detection rate of PSMA PET using different ligands in men with biochemical recurrent prostate cancer following radical treatment: a systematic review and meta …
Background Despite the acknowledged diagnostic detection rate of prostate-specific
membrane antigen (PSMA) positron emission tomography (PET) imaging in prostate cancer …
membrane antigen (PSMA) positron emission tomography (PET) imaging in prostate cancer …
Hybrid imaging with [68Ga]PSMA-11 PET-CT and PET-MRI in biochemically recurrent prostate cancer
PA Glemser, LT Rotkopf, CH Ziener… - Cancer Imaging, 2022 - Springer
Abstract Aim To compare [68Ga] PSMA-11 PET-CT,[68Ga] PSMA-11 PET-MRI and MRI in a
cohort of prostate cancer (PCa) patients in biochemical recurrence after initial curative …
cohort of prostate cancer (PCa) patients in biochemical recurrence after initial curative …
68Ga-RM2 PET–MRI versus MRI alone for evaluation of patients with biochemical recurrence of prostate cancer: a single-centre, single-arm, phase 2/3 imaging trial
Summary Background National Comprehensive Cancer Network guidelines include
prostate-specific membrane antigen (PSMA)-targeted PET for detection of biochemical …
prostate-specific membrane antigen (PSMA)-targeted PET for detection of biochemical …
[HTML][HTML] Cyclotron vs generator-produced 68Ga PSMA: a single-institution, prospective clinical trial
J Martinez, K Subramanian, SH Castellanos… - Translational …, 2023 - Elsevier
The clinical utility of gallium 68 (68 Ga)-PSMA PET for the diagnosis and management of
prostate cancer is driven in part by radioisotope availability and production costs. This study …
prostate cancer is driven in part by radioisotope availability and production costs. This study …
Reawakening of nuclear medicine through molecular imaging: quantitative theranostics and PSMA PET
AC Civelek - Radiology, 2023 - pubs.rsna.org
Dr Civelek is an academic nuclear medicine physician who was previously the deputy
director of nuclear medicine and clinical director at the National Institutes of Health Clinical …
director of nuclear medicine and clinical director at the National Institutes of Health Clinical …
Prostate-specific membrane antigen-based PET brings new insights into the management of prostate cancer
C Hu, L Dong, W Xue, KJ Pienta - PET clinics, 2022 - pet.theclinics.com
Prostate cancer (PCa) is the third most common cancer diagnosed in the world, with 1.4
million cases diagnosed and approximately 375,000 men reported dead in 2020. 1 …
million cases diagnosed and approximately 375,000 men reported dead in 2020. 1 …
Failure patterns by PSMA PET for recurrent prostate cancer after prostatectomy and salvage radiation
Objective To characterize patterns of failure using prostate-specific membrane antigen
positron emission tomography (PSMA PET) after radical prostatectomy (RP) and salvage …
positron emission tomography (PSMA PET) after radical prostatectomy (RP) and salvage …
[HTML][HTML] An Update on the Role of mpMRI and 68Ga-PSMA PET Imaging in Primary and Recurrent Prostate Cancer
The objective of this work was to review comparisons of the efficacy of 68 Ga-PSMA-11
(prostate-specific membrane antigen) PET/CT and multiparametric magnetic resonance …
(prostate-specific membrane antigen) PET/CT and multiparametric magnetic resonance …
Prospective Comparison of 68Ga-NeoB and 68Ga-PSMA-R2 PET/MRI in Patients with Biochemically Recurrent Prostate Cancer
Prostate-specific membrane antigen (PSMA) and gastrin-releasing peptide receptors are
both overexpressed in prostate cancer (PC) but may provide complementary information …
both overexpressed in prostate cancer (PC) but may provide complementary information …